HBIO vs JNJ · rev $22.7M vs P/E 17, rev $49.37B
Harvard Bioscience Inc (HBIO) versus Johnson & Johnson (JNJ) — a side-by-side from cached financials, not a winner call.
Harvard Bioscience Inc (HBIO) is a medical instruments & supplies company listed on US.
Johnson & Johnson (JNJ) is a drug manufacturers - general company listed on US. It is led by Joaquin Duato.
Latest reported HBIO revenue for 2026-06-30 was $22.7M. Net income was -$2.9M. Revenue was up 9.5% from 2026-03-31 to 2026-06-30. HBIO currently screens at market cap $20.3M.
Latest reported JNJ revenue for 2026-06-28 was $49.37B. Net income was $10.77B. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
HBIO currently screens at market cap $20.3M. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
Not investment advice. Open the HBIO and JNJ stock pages for the full models.
Not investment advice.